Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Author:
Publisher
Springer Science and Business Media LLC
Link
https://www.nature.com/articles/nrc.2017.121.pdf
Reference236 articles.
1. Melchers, F. Checkpoints that control B cell development. J. Clin. Invest. 125, 2203–2210 (2015).
2. Burger, J. A. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl. J. Med. 373, 2425–2437 (2015).
3. Chanan-Khan, A. et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 17, 200–211 (2016).
4. Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32–42 (2013). The first large data set, which established the activity of the BTK inhibitor ibrutinib in patients with CLL.
5. Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507–516 (2013).
Cited by 352 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Structure-based design of novel pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives as potent noncovalent Bruton's tyrosine kinase (BTK) inhibitors;Bioorganic & Medicinal Chemistry Letters;2025-09
2. The role of double-negative B cells in the pathogenesis of systemic lupus erythematosus;Autoimmunity Reviews;2025-06
3. DNA‐Engineered Modular Nanovaccines Featuring Precise Topology for Enhanced Immunogenicity;Advanced Materials;2025-05-15
4. Investigation of the mechanism of hypertension caused by BTKi in the treatment of hematologic diseases;Frontiers in Pharmacology;2025-05-15
5. Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study;Expert Opinion on Drug Metabolism & Toxicology;2025-04-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.7亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2025 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3